Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 3/20 | 0.34 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.34 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974541 | 0.79 | CA1 (0.55) | CA1ALDH1A1BLMCYP1A2P2RX7 | |
| SCHEMBL8864311 | 0.78 | ALDH1A1 (0.39) | RNPEPALDH1A1SLC7A5 | |
| SCHEMBL2340413 | 0.78 | RNPEP (0.38) | RNPEPKISS1RALDH1A1SLC7A5 | |
| SCHEMBL5872275 | 0.77 | CA1 (0.52) | CA1ALDH1A1BLMCYP1A2P2RX7 | |
| SCHEMBL110531 | 0.74 | CA1 (0.60) | CA1ALDH1A1BLMCYP1A2 | |
| SCHEMBL2213202 | 0.73 | CA1 (0.48) | CA1ANPEPFOLH1BLMCYP1A2 | |
| SCHEMBL11051339 | 0.73 | PHF8 (0.52) | CA1KISS1RALDH1A1P2RX7 | |
| SCHEMBL14350722 | 0.71 | CA1 (0.57) | CA1ALDH1A1BLMCYP1A2P2RX7 | |
| SCHEMBL29894122 | 0.70 | CA1 (0.62) | CA1ANPEPRNPEPDNPEPP2RX7 | |
| SCHEMBL12722976 | 0.70 | PHF8 (0.48) | CA1ALDH1A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270139-A1 | CATHODE MATERIAL FOR A FUEL CELL, CATHODE INCLUDING THE CATHODE MATERIAL, AND A SOLID OXIDE FUEL CELL INCLUDING THE CATHODE MATERIAL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-8003355-B2 | Polymer extraction methods | METABOLIX, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7981642-B2 | Polymer extraction methods | METABOLIX, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7795376-B2 | Single solvent polymer extraction methods | METABOLIX INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100196997-A1 | POLYMER EXTRACTION METHODS | METABOLIX, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100197885-A1 | POLYMER EXTRACTION METHODS | METABOLIX, INC. | 2010-08-05 | — | — | US | disclosed |
| US-7713720-B2 | Polymer extraction methods | METABOLIX INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100016544-A1 | SINGLE SOLVENT POLYMER EXTRACTION METHODS | CJ CHEILJEDANG CORPORATION (KR) | 2010-01-21 | — | — | US | disclosed |
| US-20070278157-A1 | Polymer Extraction Methods | METABOLIX INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070105923-A1 | Substantially pure olmesartan medoxomil and processes for its preparation | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105923-A1 | Substantially pure olmesartan medoxomil and processes for its preparation | MED1, CYP4A11, REN | CA1 3927/4885ANPEP 1632/4885RNPEP 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.